RT Journal Article
SR Electronic
T1 Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004656
DO 10.1136/jitc-2022-004656
VO 10
IS 4
A1 Xia, Yongxiang
A1 Tang, Weiwei
A1 Qian, Xiaofeng
A1 Li, Xiangcheng
A1 Cheng, Feng
A1 Wang, Ke
A1 Zhang, Feng
A1 Zhang, Chuanyong
A1 Li, Donghua
A1 Song, Jinhua
A1 Zhang, Hui
A1 Zhao, Jie
A1 Yao, Aihua
A1 Wu, Xiaofeng
A1 Wu, Chen
A1 Ji, Guwei
A1 Liu, Xisheng
A1 Zhu, Feipeng
A1 Qin, Lang
A1 Xiao, Xuan
A1 Deng, Zhenhua
A1 Kong, Xiangyi
A1 Li, Si
A1 Yu, Yangyang
A1 Xi, Wenjing
A1 Deng, Wanglong
A1 Qi, Chuang
A1 Liu, Hanyuan
A1 Pu, Liyong
A1 Wang, Ping
A1 Wang, Xuehao
YR 2022
UL http://jitc.bmj.com/content/10/4/e004656.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.